POM-V Prescription Required Companion Animal

Vominil 10 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Maropitant

Form

Injection

Species

Cats Dogs

Manufacturer

VetViva Richter GmbH

VMD MA No.

57446/5004

What it's used for

Dogs • • • • recovery from general anaesthesia after use of the µ-opiate receptor agonist morphine. Cats • induced by motion sickness. • Revised: October 2...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Maropitant

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Vominil 10 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Dogs
•
•
•
•
recovery from general anaesthesia after use of the µ-opiate receptor agonist
morphine.
Cats
•
induced by motion sickness.
•

Revised: October 2025
AN: 01090/2025

For subcutaneous or intravenous use.
The veterinary medicinal product should be injected subcutaneously or
intravenously, once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg
bodyweight) for up to 5 consecutive days. Intravenous administration of the
veterinary medicinal product should be given as a single bolus without mixing
the product with any other fluids.
To ensure a correct dosage, body weight should be determined as accurately
as possible.
To prevent vomiting, the veterinary medicinal product should be administered
more than 1 hour in advance. The duration of effect is approximately 24 h and
therefore treatment can be given the night before administration of an agent that
may cause emesis e.g. chemotherapy.
As the pharmacokinetic variation is large and maropitant accumulates in the
body after once daily repeated administration, lower doses than recommended
might be sufficient in some individuals and when repeating the dose.
For administration by subcutaneous injection, see also ‘special precautions for
use’ (section 4.5).

Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

Dogs and cats:
Very common
(>1 animal / 10 animals
treated):
Injection site pain*Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Anaphylactic-type reaction, allergic oedema,
urticaria, erythema, collapse, dyspnoea, pale
mucous membrane;
Lethargy;
Neurological disorders (e.g. ataxia, convulsion/
seizure, muscle tremor)

*May occur when injected subcutaneously. In approximately one third of cats
moderate to severe response to injection is observed.

Revised: October 2025
AN: 01090/2025
Page 4 of 8Reporting adverse events is important. It allows continuous safety monitoring of
a veterinary medicinal product. Reports should be sent, preferably via a
veterinarian, to either the marketing authorisation holder or its local
representative or the national competent authority via the national reporting
system. See also the last section of the package leaflet for respective contact
details.

Vomiting can be associated with serious, severely debilitating conditions
including gastrointestinal obstructions; therefore, appropriate diagnostic
evaluations should be employed.
Good veterinary practice indicates that antiemetics should be used in
conjunction with other veterinary and supportive measures such as dietary
control and fluid replacement therapy while addressing the underlying causes of
the vomiting.
The use of the veterinary medicinal product against vomiting due to motion
sickness is not recommended.
Dogs:
Although maropitant has been demonstrated to be effective in both the
treatment and prevention of emesis induced by chemotherapy, it was found
more efficacious if used preventively. Therefore, it is recommended to
administer the antiemetic prior to administration of the chemotherapeutic agent.
Cats:
The efficacy of maropitant in reduction of nausea was demonstrated in studies
using a model (xylazine-induced nausea).

i). Special precautions for use in animals
The safety of the veterinary medicinal product has not been established in dogs
less than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant
or lactating dogs and cats. Use only according to the benefit-risk assessment by
the responsible veterinarian.
Maropitant is metabolised in the liver and therefore should be used with caution
in patients with hepatic disease. As maropitant is accumulated in the body
during a 14-day treatment period due to metabolic saturation, careful monitoring
of liver function and any adverse events should be implemented during long
term treatment.
The veterinary medicinal product should be used with caution in animals
suffering from or with predisposition for cardiac diseases as maropitant has
affinity to Ca- and K-ion channels. Increases of approximately 10% in the QT
interval of the ECG were observed in a study on healthy beagle dogs
administered 8 mg/kg orally; however, such an increase is unlikely to be of
clinical significance.

Revised: October 2025
AN: 01090/2025
Due to the frequent occurrence of transient pain during subcutaneous injection,
appropriate animal restraining measures may have to be applied. Injecting the
veterinary medicinal product at refrigerated temperature may reduce pain at
injection.
ii). Special precautions to be taken by the person administering the veterinary
medicinal product to animals
This product may cause skin sensitisation. People with known hypersensitivity
to maropitant should administer the veterinary medicinal product with caution.
Wash the exposed skin immediately after exposure with large amounts of water.
If you develop symptoms such as a rash after accidental exposure, seek
medical advice and show the physician this warning.
This veterinary medicinal product may be irritant to the eyes. Avoid eye contact.
In case of accidental contact of the product with eyes rinse abundantly with
fresh water. If symptoms occur, seek the advice of a physician.
Maropitant is a neurokinin-1 (NK1) receptor antagonist that acts in the central
nervous system. Accidental self-injection or ingestion may result in nausea,
dizziness and somnolence. Care should be taken to avoid accidental self-
injection. In case of accidental oral intake or self-injection seek medical advice
immediately and show the package leaflet or the label to the physician.
Wash hands after use.
Special precautions for the protection of the environment
Not applicable.
iii). Other precautions
Not applicable.

The veterinary medicinal product should not be used concomitantly with Ca-
channel antagonists as maropitant has affinity to Ca-channels.
Maropitant is highly bound to plasma proteins and may compete with other
highly bound medicines.

Do not freeze.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.